Jacques P Tremblay

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 21

Top Topics

Top Venues

Journal of clinical medicine

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Eli BenDavid, Sina Ramezanian, Yaoyao Lu, Joël Rousseau, Avi Schroeder, Marc Lavertu, Jacques P Tremblay
Emerging Perspectives on Prime Editor Delivery to the Brain. Pharmaceuticals (Basel, Switzerland) 17 (6) (2024)
Eli BenDavid, Sina Ramezanian, Yaoyao Lu, Joël Rousseau, Avi Schroeder, Marc Lavertu, Jacques P Tremblay
Emerging Perspectives on Prime Editor Delivery to the Brain. Pharmaceuticals (Basel, Switzerland) 17 (6) (2024)
Pouiré Yaméogo, Catherine Gérard, Nathalie Majeau, Jacques P Tremblay
Removal of the GAA repeat in the heart of a Friedreich's ataxia mouse model using CjCas9. Gene therapy (2023)
Camille Bouchard, Jacques P Tremblay
Portrait of Dysferlinopathy: Diagnosis and Development of Therapy. Journal of clinical medicine 12 (18) (2023)
Kelly Godbout, Jacques P Tremblay
Prime Editing for Human Gene Therapy: Where Are We Now? Cells 12 (4) (2023)
Pouiré Yaméogo, Nathalie Majeau, Cedric Happi Mbakam, Jacques P Tremblay
Small-molecule inhibitors of proteasome increase CjCas9 protein stability. PloS one 18 (1) (2023)
Kelly Godbout, Joël Rousseau, Jacques P Tremblay
Successful Correction by Prime Editing of a Mutation in the RYR1 Gene Responsible for a Myopathy. Cells 13 (1) (2023)
Kelly Godbout, Joël Rousseau, Jacques P Tremblay
Successful Correction by Prime Editing of a Mutation in the RYR1 Gene Responsible for a Myopathy. Cells 13 (1) (2023)
Pouiré Yaméogo, Nathalie Majeau, Cedric Happi Mbakam, Jacques P Tremblay
Small-molecule inhibitors of proteasome increase CjCas9 protein stability. PloS one 18 (1) (2023)
Kelly Godbout, Jacques P Tremblay
Prime Editing for Human Gene Therapy: Where Are We Now? Cells 12 (4) (2023)
Camille Bouchard, Catherine Gérard, Solange Gni-Fiene Yanyabé, Nathalie Majeau, Malek Aloui, Gabrielle Buisson, Pouiré Yaméogo, Vanessa Couture, Jacques P Tremblay
Finding an Appropriate Mouse Model to Study the Impact of a Treatment for Friedreich Ataxia on the Behavioral Phenotype. Genes 14 (8) (2023)
Kelly Godbout, Joël Rousseau, Jacques P Tremblay
Successful Correction by Prime Editing of a Mutation in the RYR1 Gene Responsible for a Myopathy. Cells 13 (1) (2023)
Kelly Godbout, Joël Rousseau, Jacques P Tremblay
Successful Correction by Prime Editing of a Mutation in the RYR1 Gene Responsible for a Myopathy. Cells 13 (1) (2023)
Pouiré Yaméogo, Nathalie Majeau, Cedric Happi Mbakam, Jacques P Tremblay
Small-molecule inhibitors of proteasome increase CjCas9 protein stability. PloS one 18 (1) (2023)
Pouiré Yaméogo, Nathalie Majeau, Cedric Happi Mbakam, Jacques P Tremblay
Small-molecule inhibitors of proteasome increase CjCas9 protein stability. PloS one 18 (1) (2023)
Pouiré Yaméogo, Nathalie Majeau, Cedric Happi Mbakam, Jacques P Tremblay
Small-molecule inhibitors of proteasome increase CjCas9 protein stability. PloS one 18 (1) (2023)
Camille Bouchard, Jacques P Tremblay
Limb-Girdle Muscular Dystrophies Classification and Therapies. Journal of clinical medicine 12 (14) (2023)
Kelly Godbout, Jacques P Tremblay
Prime Editing for Human Gene Therapy: Where Are We Now? Cells 12 (4) (2023)
Kelly Godbout, Joël Rousseau, Jacques P Tremblay
Successful Correction by Prime Editing of a Mutation in the RYR1 Gene Responsible for a Myopathy. Cells 13 (1) (2023)
Kelly Godbout, Jacques P Tremblay
Delivery of RNAs to Specific Organs by Lipid Nanoparticles for Gene Therapy. Pharmaceutics 14 (10) (2022)
Cedric Happi Mbakam, Gabriel Lamothe, Guillaume Tremblay, Jacques P Tremblay
CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 19 (3) (2022)